

Errata

Monfardini S, Rilke F, Valagussa P *et al.* A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. *Eur J Cancer Clin Oncol* 1984, **20**, 609-617.

The authors wish to apologise for a mistake incurred in this paper. The first sentence in the second column of p. 614 should read:

The apparent discrepancy between relatively low relapse and low survival rates for group H (and immunoblastic) compared to group G (and immunocentric) is explained by the fact that patients who did not achieve a CR had a median survival of 16.5 months in group G and 9 months in group H.

Bowen D, Bailey BD, Guernsey LA. Rate-limiting steps in the interactions of fluoropyrimidines and methotrexate. *Eur J Cancer Clin Oncol* 1984, **20**, 651-657.

The authors apologise for a mistake in the Discussion section of this paper. The second sentence of the second column on p. 656 should read:

However, even in the presence of MTX, DHF is converted to THF [26] and hence to 5,10-CH₂-THF. Fluoropyrimidines, after conversion to FdUMP, can now trap the 5,10-CH₂-THF, which formed in the presence of MTX, to further decrease the availability of reduced folates for amino acid synthesis and purine synthesis.